147 related articles for article (PubMed ID: 29130632)
1. DOCK3-related neurodevelopmental syndrome: Biallelic intragenic deletion of DOCK3 in a boy with developmental delay and hypotonia.
Iwata-Otsubo A; Ritter AL; Weckselbatt B; Ryan NR; Burgess D; Conlin LK; Izumi K
Am J Med Genet A; 2018 Jan; 176(1):241-245. PubMed ID: 29130632
[TBL] [Abstract][Full Text] [Related]
2. Biallelic loss-of-function variants in DOCK3 cause muscle hypotonia, ataxia, and intellectual disability.
Helbig KL; Mroske C; Moorthy D; Sajan SA; Velinov M
Clin Genet; 2017 Oct; 92(4):430-433. PubMed ID: 28195318
[TBL] [Abstract][Full Text] [Related]
3. Variants in DOCK3 cause developmental delay and hypotonia.
Wiltrout K; Ferrer A; van de Laar I; Namekata K; Harada T; Klee EW; Zimmerman MT; Cousin MA; Kempainen JL; Babovic-Vuksanovic D; van Slegtenhorst MA; Aarts-Tesselaar CD; Schnur RE; Andrews M; Shinawi M
Eur J Hum Genet; 2019 Aug; 27(8):1225-1234. PubMed ID: 30976111
[TBL] [Abstract][Full Text] [Related]
4.
Alexander MS; Velinov M
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895289
[TBL] [Abstract][Full Text] [Related]
5. Dock GEFs and their therapeutic potential: neuroprotection and axon regeneration.
Namekata K; Kimura A; Kawamura K; Harada C; Harada T
Prog Retin Eye Res; 2014 Nov; 43():1-16. PubMed ID: 25016980
[TBL] [Abstract][Full Text] [Related]
6. Dock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex.
Namekata K; Harada C; Taya C; Guo X; Kimura H; Parada LF; Harada T
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7586-91. PubMed ID: 20368433
[TBL] [Abstract][Full Text] [Related]
7. DOCK3 regulates normal skeletal muscle regeneration and glucose metabolism.
Samani A; Karuppasamy M; English KG; Siler CA; Wang Y; Widrick JJ; Alexander MS
FASEB J; 2023 Oct; 37(10):e23198. PubMed ID: 37742307
[TBL] [Abstract][Full Text] [Related]
8. DOCK3 is a dosage-sensitive regulator of skeletal muscle and Duchenne muscular dystrophy-associated pathologies.
Reid AL; Wang Y; Samani A; Hightower RM; Lopez MA; Gilbert SR; Ianov L; Crossman DK; Dell'Italia LJ; Millay DP; van Groen T; Halade GV; Alexander MS
Hum Mol Genet; 2020 Oct; 29(17):2855-2871. PubMed ID: 32766788
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer.
Zhu X; Gao G; Chu K; Yang X; Ren S; Li Y; Wu H; Huang Y; Zhou C
Int J Biochem Cell Biol; 2015 Apr; 61():103-14. PubMed ID: 25687035
[TBL] [Abstract][Full Text] [Related]
10. Dock3 Participate in Epileptogenesis Through rac1 Pathway in Animal Models.
Li J; Mi X; Chen L; Jiang G; Wang N; Zhang Y; Deng W; Wang Z; Chen G; Wang X
Mol Neurobiol; 2016 May; 53(4):2715-25. PubMed ID: 26319681
[TBL] [Abstract][Full Text] [Related]
11. A 137-kb deletion within the Potocki-Shaffer syndrome interval on chromosome 11p11.2 associated with developmental delay and hypotonia.
Montgomery ND; Turcott CM; Tepperberg JH; McDonald MT; Aylsworth AS
Am J Med Genet A; 2013 Jan; 161A(1):198-202. PubMed ID: 23239541
[TBL] [Abstract][Full Text] [Related]
12. Isolated chromosome 8p23.2‑pter deletion: Novel evidence for developmental delay, intellectual disability, microcephaly and neurobehavioral disorders.
Shi S; Lin S; Chen B; Zhou Y
Mol Med Rep; 2017 Nov; 16(5):6837-6845. PubMed ID: 28901431
[TBL] [Abstract][Full Text] [Related]
13. A girl with developmental delay, ataxia, cranial nerve palsies, severe respiratory problems in infancy-Expanding NDST1 syndrome.
Armstrong L; Tarailo-Graovac M; Sinclair G; Seath KI; Wasserman WW; Ross CJ; van Karnebeek CD
Am J Med Genet A; 2017 Mar; 173(3):712-715. PubMed ID: 28211985
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection and axon regeneration by novel low-molecular-weight compounds through the modification of DOCK3 conformation.
Namekata K; Tsuji N; Guo X; Nishijima E; Honda S; Kitamura Y; Yamasaki A; Kishida M; Takeyama J; Ishikawa H; Shinozaki Y; Kimura A; Harada C; Harada T
Cell Death Discov; 2023 May; 9(1):166. PubMed ID: 37188749
[TBL] [Abstract][Full Text] [Related]
15. Dock3 regulates BDNF-TrkB signaling for neurite outgrowth by forming a ternary complex with Elmo and RhoG.
Namekata K; Watanabe H; Guo X; Kittaka D; Kawamura K; Kimura A; Harada C; Harada T
Genes Cells; 2012 Aug; 17(8):688-97. PubMed ID: 22734669
[TBL] [Abstract][Full Text] [Related]
16. CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-β-catenin-WAVE2 signaling.
Cui HY; Wang SJ; Miao JY; Fu ZG; Feng F; Wu J; Yang XM; Chen ZN; Jiang JL
Oncotarget; 2016 Feb; 7(5):5613-29. PubMed ID: 26716413
[TBL] [Abstract][Full Text] [Related]
17. Molecular cytogenetic characterization of 2p23.2p23.3 deletion in a child with developmental delay, hypotonia and cryptorchism.
Rocca MS; Faletra F; Devescovi R; Gasparini P; Pecile V
Eur J Med Genet; 2013 Jan; 56(1):62-5. PubMed ID: 23142270
[TBL] [Abstract][Full Text] [Related]
18. Dual genetic diagnoses: Atypical hand-foot-genital syndrome and developmental delay due to de novo mutations in HOXA13 and NRXN1.
Wallis M; Tsurusaki Y; Burgess T; Borzi P; Matsumoto N; Miyake N; True D; Patel C
Am J Med Genet A; 2016 Mar; 170(3):717-24. PubMed ID: 26590955
[TBL] [Abstract][Full Text] [Related]
19. Dock3-NMDA receptor interaction as a target for glaucoma therapy.
Kimura A; Namekata K; Guo X; Harada C; Harada T
Histol Histopathol; 2017 Mar; 32(3):215-221. PubMed ID: 27615513
[TBL] [Abstract][Full Text] [Related]
20. Further delineation of TBCK - Infantile hypotonia with psychomotor retardation and characteristic facies type 3.
Zapata-Aldana E; Kim DD; Remtulla S; Prasad C; Nguyen CT; Campbell C
Eur J Med Genet; 2019 Apr; 62(4):273-277. PubMed ID: 30103036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
